Barclays PLC Ab Cellera Biologics Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Barclays PLC holds 43,028 shares of ABCL stock, worth $252,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,028
Previous 43,028
-0.0%
Holding current value
$252,144
Previous $148,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ABCL
# of Institutions
151Shares Held
115MCall Options Held
488KPut Options Held
476K-
Baker Bros. Advisors LP New York, NY27.5MShares$161 Million0.96% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$78.3 Million0.01% of portfolio
-
Baillie Gifford & CO10.4MShares$60.7 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL8.47MShares$49.6 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$26.6 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.67B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...